Inovio Pharma (INO) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.22), $0.05 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $125 thousand versus the consensus estimate of $339.28 thousand.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Nebius Group prices upsized $5B convertible notes offering
- Accuray (ARAY) Tops Q4 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
